These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 19431075)

  • 1. Angiogenesis inhibitors for the treatment of chronic autoimmune inflammatory arthritis.
    Schoettler N; Brahn E
    Curr Opin Investig Drugs; 2009 May; 10(5):425-33. PubMed ID: 19431075
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Angiogenesis--a new target for future therapy.
    Pandya NM; Dhalla NS; Santani DD
    Vascul Pharmacol; 2006 May; 44(5):265-74. PubMed ID: 16545987
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Angiogenesis: potentials for pharmacologic intervention in the treatment of cancer, cardiovascular diseases, and chronic inflammation.
    Griffioen AW; Molema G
    Pharmacol Rev; 2000 Jun; 52(2):237-68. PubMed ID: 10835101
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Angiogenesis: a therapeutic target in arthritis.
    Walsh DA; Haywood L
    Curr Opin Investig Drugs; 2001 Aug; 2(8):1054-63. PubMed ID: 11892913
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Angiogenesis as a therapeutic target in arthritis in 2011: learning the lessons of the colorectal cancer experience.
    Thairu N; Kiriakidis S; Dawson P; Paleolog E
    Angiogenesis; 2011 Sep; 14(3):223-34. PubMed ID: 21431303
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of angiogenic pathways in rheumatoid arthritis: potential for therapeutic targeting.
    Veale DJ; Fearon U
    Best Pract Res Clin Rheumatol; 2006 Oct; 20(5):941-7. PubMed ID: 16980216
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Imbalance in production between vascular endothelial growth factor and endostatin in patients with rheumatoid arthritis.
    Nagashima M; Asano G; Yoshino S
    J Rheumatol; 2000 Oct; 27(10):2339-42. PubMed ID: 11036826
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of vascular endothelial growth factor (VEGF) and VEGF receptors in tumor angiogenesis and malignancies.
    Pradeep CR; Sunila ES; Kuttan G
    Integr Cancer Ther; 2005 Dec; 4(4):315-21. PubMed ID: 16282508
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Angiogenesis inhibitors in cancer therapy.
    Dredge K; Dalgleish AG; Marriott JB
    Curr Opin Investig Drugs; 2003 Jun; 4(6):667-74. PubMed ID: 12901224
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Neoplasms and angiogenesis].
    Lewy-Trenda I
    Pol Merkur Lekarski; 2002 Sep; 13(75):225-8. PubMed ID: 12474576
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment with the angiogenesis inhibitor endostatin: a novel therapy in rheumatoid arthritis.
    Matsuno H; Yudoh K; Uzuki M; Nakazawa F; Sawai T; Yamaguchi N; Olsen BR; Kimura T
    J Rheumatol; 2002 May; 29(5):890-5. PubMed ID: 12022345
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Angiogenesis in rheumatoid arthritis: a disease specific process or a common response to chronic inflammation?
    Marrelli A; Cipriani P; Liakouli V; Carubbi F; Perricone C; Perricone R; Giacomelli R
    Autoimmun Rev; 2011 Aug; 10(10):595-8. PubMed ID: 21545851
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vivo inhibition of angiogenesis by interleukin-13 gene therapy in a rat model of rheumatoid arthritis.
    Haas CS; Amin MA; Ruth JH; Allen BL; Ahmed S; Pakozdi A; Woods JM; Shahrara S; Koch AE
    Arthritis Rheum; 2007 Aug; 56(8):2535-48. PubMed ID: 17665443
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Growth hormone, VEGF and FGF: involvement in rheumatoid arthritis.
    Malemud CJ
    Clin Chim Acta; 2007 Jan; 375(1-2):10-9. PubMed ID: 16893535
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potential future targets for treating ocular neovascularization.
    Barouch FC; Miller JW
    Ophthalmol Clin North Am; 2006 Sep; 19(3):401-9. PubMed ID: 16935215
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Receptor tyrosine kinase inhibitors as anti-angiogenic agents.
    Kim DW; Lu B; Hallahan DE
    Curr Opin Investig Drugs; 2004 Jun; 5(6):597-604. PubMed ID: 15242247
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human inflammatory synovial fibroblasts induce enhanced myeloid cell recruitment and angiogenesis through a hypoxia-inducible transcription factor 1alpha/vascular endothelial growth factor-mediated pathway in immunodeficient mice.
    del Rey MJ; Izquierdo E; Caja S; Usategui A; Santiago B; Galindo M; Pablos JL
    Arthritis Rheum; 2009 Oct; 60(10):2926-34. PubMed ID: 19790065
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of vascular endothelial growth factor (VEGF) as a novel approach for cancer therapy.
    Wood JM
    Medicina (B Aires); 2000; 60 Suppl 2():41-7. PubMed ID: 11188930
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The histone deacetylase inhibitor NVP-LAQ824 inhibits angiogenesis and has a greater antitumor effect in combination with the vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584.
    Qian DZ; Wang X; Kachhap SK; Kato Y; Wei Y; Zhang L; Atadja P; Pili R
    Cancer Res; 2004 Sep; 64(18):6626-34. PubMed ID: 15374977
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pyridylmethylthio derivatives as VEGF inhibitors: part 2.
    Tajima H; Honda T; Kawashima K; Sasabuchi Y; Yamamoto M; Ban M; Okamoto K; Inoue K; Inaba T; Takeno Y; Tsuboi T; Tonouchi A; Aono H
    Bioorg Med Chem Lett; 2011 Feb; 21(4):1232-5. PubMed ID: 21247763
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.